多中心成骨肉瘤的治疗

目的探讨多中心成骨肉瘤的治疗方法。方法1998年1月至2005年6月治疗多中心成骨肉瘤患者9例，男7例，女2例。9例患者的临床特征、影像学表现、病理学检查均证实多中心成骨肉瘤的诊断。其中6例患者初诊时即存在多发骨肉瘤病灶；3例初诊时为单一骨肉瘤病灶，而后分别在确诊6、8、11个月出现第二处骨肉瘤病灶。1例患者因经济原因放弃治疗，其余8例患者接受阿霉素60mg／m^2,顺铂100mg／m^2,氨甲蝶呤8-12g／m^2长春新碱1．4mg／m^2、异环磷酰胺12．5g／m^2化疗1周期。化疗后根据病灶数目、部位以及对化疗的反应等决定包括手术、化疗在内的进一步治疗方案。对病灶数目较少、病灶可广泛切除的患者，如果化疗反应好，则在化疗的基础上广泛切除肿瘤，手术原则同单发性骨肉瘤；如果全身病灶数目多、部分病灶位于中轴骨等不易广泛切除的部位，则根据病情采取适当的姑息手术。对上述化疗反应差的患者，应用三氧化二砷、紫杉醇、VP-16化疗。结果放弃治疗的1例患者于确诊5个月后死于肿瘤引起的全身衰竭，5例初诊存在多发骨肉瘤病灶的患者平均生存时间9．8个月，其中2例对化疗反应好且完成4周期以上化疗的患者平均生存时间为15个月，对化疗反应差以及未能完成化疗的3例患者平均生存时间仅为7．1个月。3例病灶不同时出现的多中心成骨肉瘤患者平均随访2年，2例带瘤生存，无肺转移；1例无瘤生存。结论多中心成骨肉瘤预后较差，经积极的化疗，能够延长患者生命，改善预后。

Treatment of multifocal osteosarcoma

Objective To discuss the treatment and prognosis of multifocal osteosarcoma. Methods Between January 1998 and June 2005, nine patients(seven males and two females), six with synchronous multifocal osteosarcoma and three with metachronous multifocal osteosarcoma were treated in our department. The diagnosis of multifocal osteosarcoma was confirmed by clinical presentation, radiology and pathology. Eight of the nine patients received chemotherapy with adriamycin(60 mg/m2), cisplatinum(100 mg/m2), high-dose methotrexate(8-12 g/m2), vincristine(1.4 mg/m2), ifosfamide(12.5 g/m2), and G-CSF. Based on the response to primary chemotherapy, further chemotherapy plans were made, and different operations were done to control local lesions or to relieve symptoms. Arsenous acid, paclitaxel and VP-16 were used in patients who responded poorly to primary chemotherapy. Results One patient who given up remedy was died in systematic fail due to the cancer after 5 month, five patients who were diagnosed synchronous multifocal osteosarcoma died from progressive disease in 3.5 to 17 months (mean time was 9.8 months). Only two of them had a good response to chemotherapy and had finished at least four cycles of chemotherapy,and they had a better survival time of 15 and 17 months respectively. Three patients with metachronous multifocal osteosarcoma had a better prognosis. After a two-year follow-up, two lived with disease and one lived without disease. Conclusion The prognosis of patients with multifocal osteosarcoma is poor, and patients with metachronous multifocal osteosarcoma have a relatively better prognosis. To improve the prognosis of patients with multifocal osteosarcoma, aggressive chemother-apeutics are needed.